New Enterprise Associates 15, L.P. filed a Form 144 notice on November 20, 2026, disclosing a proposed sale of 114,412 shares of Senti Biosciences Inc common stock through J.P. Morgan Securities LLC.

Key Highlights

  • Proposed seller: New Enterprise Associates 15, L.P., identified in the filing as a former affiliate of Senti Biosciences Inc.
  • Shares proposed for sale: 114,412 shares of common stock, with an aggregate market value of $319,209 according to the filing.
  • Shares outstanding: The filing lists 85,706,263 shares of common stock outstanding.
  • Approximate sale date: November 20, 2026, through broker J.P. Morgan Securities LLC, on Nasdaq.
  • Acquisition history: The shares were acquired across seven private placement transactions from the issuer, spanning July 28, 2016 through December 9, 2024.
  • Recent sales: The filing reports nothing to report under securities sold during the past 3 months.

New Enterprise Associates 15 Proposes Rule 144 Sale of Senti Biosciences Common Stock

According to the Form 144 filing submitted to the SEC on November 20, 2026, New Enterprise Associates 15, L.P., a former affiliate of Senti Biosciences Inc (Nasdaq), is proposing to sell 114,412 shares of the company's common stock. The filing lists an aggregate market value of $319,209 for the shares to be sold, with 85,706,263 shares of common stock outstanding at the time of the notice. J.P. Morgan Securities LLC, located at 270 Park Avenue, 10th Floor, New York, NY 10017, is named as the broker for the proposed transaction.

The filing details seven separate acquisitions of common stock by New Enterprise Associates 15, L.P. from the issuer, all via private placement and paid in cash. These acquisitions occurred on July 28, 2016 (725 shares), February 9, 2018 (5,210 shares), January 18, 2019 (2,063 shares), August 20, 2020 (1,604 shares), November 1, 2020 (22 shares), June 8, 2022 (3,788 shares), and December 9, 2024 (101,000 shares), according to the filing.

The filing was signed by J.P. Morgan Securities LLC as agent and attorney-in-fact for New Enterprise Associates 15, L.P. The notice states that the person for whose account the securities are to be sold represents that they do not know of any material adverse information regarding the current and prospective operations of the issuer that has not been publicly disclosed. No securities of Senti Biosciences were reported as sold by this person in the three months prior to the filing date.

What Was Disclosed

New Enterprise Associates 15, L.P. filed a Rule 144 notice proposing the sale of 114,412 Senti Biosciences Inc common shares with an aggregate market value of $319,209, through J.P. Morgan Securities LLC on Nasdaq, with an approximate sale date of November 20, 2026.